3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Dermatologic
1
Conditions
Leukemia, Myeloid, Acute
3
Fallopian Tube Neoplasms
3
Ovarian Neoplasms
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Carcinoma, Ovarian Epithelial
2
Urinary Bladder Neoplasms
1
Thymoma
1
Solitary Fibrous Tumor, Pleural
1
Sarcoma
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Myelodysplastic Syndromes
1
Mesothelioma, Malignant
1
Mediastinal Neoplasms
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Liver Diseases
1
Leukemia-Lymphoma, Adult T-Cell
1
Congenital Abnormalities
1
Carcinoma, Hepatocellular
1
Burkitt Lymphoma
1
Brenner Tumor
1
Interventions
Cyclophosphamide
15
romidepsin
9
Whole-Body Irradiation
9
fludarabine phosphate
8
Vincristine
8
Etoposide
8
Doxorubicin
8
Prednisone
7
Peripheral Blood Stem Cell Transplantation
7
Mycophenolic Acid
7
Brentuximab Vedotin
6
10-propargyl-10-deazaaminopterin
6
Rituximab
5
Granulocyte Colony-Stimulating Factor
5
Gemcitabine
5
Cyclosporine
5
denileukin diftitox
4
Nivolumab
4
Lenalidomide
4
mogamulizumab
3
Tacrolimus
3
Methotrexate
3
Immunohistochemistry
3
Gene Expression Profiling
3
Dexamethasone
3
Alemtuzumab
3
selinexor
2
pembrolizumab
2
pegfilgrastim
2
liposomal doxorubicin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has results
×
Lymphoma, T-Cell, Peripheral
×
belinostat
×
Clear all
NCT00865969
2021-10-29
PTCL
Spectrum Pharmaceuticals, Inc
Phase 2
Completed
129 enrolled
12 charts
NCT00274651
2015-07-28
PXD101-CLN-6
Valerio Therapeutics
Phase 2
Terminated
53 enrolled
12 charts